International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN. 

Precision medicine in acute pancreatitis

    , ,

Author Affiliations

  • 1Krishna Institute of Medical Sciences, Hyderabad, India
  • 2Command Hospital Northern Command, Udhampur, India
  • 3Krishna Institute of Medical Sciences, Hyderabad, India

Int. Res. J. Medical Sci., Volume 13, Issue (2), Pages 14-19, August,28 (2025)

Abstract

Acute pancreatitis is a common inflammatory condition of the pancreas. Its mortality largely depends on disease severity, with severe cases having a mortality rate of up to 50%. Despite the potential for severe progression and the associated high morbidity and mortality, no specific treatment is currently available for routine use in acute pancreatitis. Precision medicine offers a promising approach, aiming to identify and apply personalized treatment strategies that can effectively reduce the burden of this disease on patients and healthcare systems.

References

  1. van Dijk SM, Hallensleben NDL, van Santvoort HC, Fockens P, van Goor H, Bruno MJ, et al. (2017)., Acute pancreatitis: recent advances through randomised trials., Gut, 66(11), 2024–32.
  2. IAP, W. G., & Guidelines, A. A. P. (2013)., IAP/APA evidence-based guidelines for the management of acute pancreatitis., Pancreatology, 13(4), e1-e15.
  3. Sykiotis, G. P., Kalliolias, G. D., & Papavassiliou, A. G. (2005)., Pharmacogenetic principles in the Hippocratic writings., The Journal of Clinical Pharmacology, 45(11), 1218-1220.
  4. Osler W. (1902)., The principles and practice of medicine: designed for the use of practitioners and students of medicine., D. Appleton.
  5. Ginsburg G.S. and Phillips K.A. (2018)., Precision Medicine: From Science to Value., Health Aff Proj Hope, 37(5), 694–701.
  6. Mukherjee R, Nunes Q, Huang W and Sutton R. (2019), Precision medicine for acute pancreatitis: current status and future opportunities., Precis Clin Med, 2(2), 81–6.
  7. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. (2010)., A large-scale, consortium-based genomewide association study of asthma., N Engl J Med, 363(13), 1211–21.
  8. Whitcomb DC, LaRusch J, Krasinskas AM, Klei L, Smith JP, Brand RE, et al. (2012)., Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis., Nat Genet, 44(12), 1349–54.
  9. Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, et al. (2017)., Pharmacological interventions for acute pancreatitis., Cochrane Database Syst Rev, 4(4), CD011384.
  10. Gukovskaya AS, Pandol SJ, Gukovsky I. (2016). New insights into the pathways initiating and driving pancreatitis. Curr Opin Gastroenterol, 32(5):429–35., undefined, undefined
  11. Felderbauer P, Müller C, Bulut K, Belyaev O, Schmitz F, Uhl W, et al. (2005)., Pathophysiology and treatment of acute pancreatitis: new therapeutic targets-a ray of hope?., Basic Clin Pharmacol Toxicol, 97(6), 342–50.
  12. Garami A, Hegyi P. (2023)., Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care., Function, 4(3), zqad015.
  13. Schepers NJ, Hallensleben NDL, Besselink MG, Anten MPGF, Bollen TL, da Costa DW, et al. (2020)., Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): A multicentre randomised controlled trial., Lancet Lond Engl, 396(10245), 167–76.
  14. Tenner S, Baillie J, DeWitt J and Vege SS (2013)., American College of Gastroenterology guideline: Management of acute pancreatitis., Am J Gastroenterol, 108(9), 1400–15; 1416.
  15. de-Madaria E, Buxbaum JL, Maisonneuve P, García García de Paredes A, Zapater P, Guilabert L, et al. (2022)., Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis., N Engl J Med, 387(11), 989–1000.
  16. de-Madaria E, Banks PA, Moya-Hoyo N, Wu BU, Rey-Riveiro M, Acevedo-Piedra NG, et al. (2014)., Early Factors Associated With Fluid Sequestration and Outcomes of Patients With Acute Pancreatitis., Clin Gastroenterol Hepatol, 12(6), 997–1002.
  17. Ding, N., Sun, Y. H., Wen, L. M., Wang, J. H., Yang, J. H., Cheng, K., ... & Chen, Q. L. (2020)., Assessment of prophylactic antibiotics administration for acute pancreatitis: A meta-analysis of randomized controlled trials., Chinese medical journal, 133(02), 212-220.
  18. Siriwardena AK, Jegatheeswaran S, Mason JM, Siriwardena AK, Jegatheeswaran S, Mason JM, et al. (2022)., A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial., Lancet Gastroenterol Hepatol, 7(10), 913–21.
  19. Singh VP, Saluja AK, Bhagat L, van Acker GJ, Song AM, Soltoff SP, et al. (2001)., Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis., J Clin Invest, 108(9), 1387–95.
  20. Mooren, F. C., V. Hlouschek, T. Finkes, S. Turi, I. A. Weber, J. Singh, W. Domschke, J. Schnekenburger, B. Kruger & M. M. Lerch. (2003)., Early changes in pancreatic acinar cell calcium signaling after pancreatic duct obstruction., J. Biol. Chem, 278, 9361 – 9369.
  21. Saluja, A. K., E. A. Donovan, K. Yamanaka, Y. Yamaguchi, B. Hofbauer & M. L. Steer. (1997)., Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B., Gastroenterology, 113, 304 – 310.
  22. Seyama, Y., T. Otani, A. Matsukura & M. Makuuchi M. (2003)., The pH modulator chloroquine blocks trypsinogen activation peptide generation in cerulein-induced pancreatitis., Pancreas, 26, 15 – 7.
  23. Gukovsky, I., C. N. Reyes, E. C. Vaquero, A. S. Gukovskaya & S. J. Pandol. (2003)., Curcumin ameliorates ethanol and nonethanol experimental pancreatitis., Amer. J. Physiol. Gastrointest. Liver Physiol, 284, G85 – 95.
  24. Foitzik, T., H. G. Hotz, B. Hotz, F. Wittig & H. J. Buhr. (2003)., Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis., Hepatogastroenterology, 50, 1159 – 1162.
  25. Sakai, Y., A. Masamune, A. Satoh, J. Nishihira, T. Yamagiwa & T. Shimosegawa (2003)., Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis., Gastroenterology, 124, 725 – 736
  26. Oruc, N., A. O. Ozutemiz, V. Yukselen, D. Nart, H. A. Celik, G. Yuce & Y. Batur. (2004)., Infliximab: a new therapeutic agent in acute pancreatitis?., Pancreas, 28, e1 – 8.
  27. Eibl, G., H. J. Buhr & T. Foitzik. (2002)., Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?., Intensive Care Med, 28, 139 – 146
  28. Johnson, C. D., A. N. Kingsnorth, C. W. Imrie, M. J. McMahon, J. P. Neoptolemos, C. McKay, S, K. Toh, P. Skaife, P. C. Leeder, P. Wilson, M. Larvin & L. D. Curtis. (2001)., Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis., Gut, 48, 62 – 69.
  29. Cavallini, G., A. Tittobello, L. Frulloni, E. Masci, A. Mariana & V. Di Francesco. (1996)., Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy–Italian Group., N. Engl. J. Med, 335, 919 – 923.
  30. Uhl, W., Büchler, M. W., Malfertheiner, P., Beger, H. G., Adler, G., Gaus, W., & German Pancreatitis Study Group. (1999)., A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis., Gut, 45(1), 97-104.
  31. Virlos, I. T., J. Mason, D. Schofield, R. F. McCloy, J. M. Eddleston & A. K. Siriwardena, (2003)., Intravenous n-acetylcysteine, ascorbic acid and selenium-based anti-oxidant therapy in severe acute pancreatitis., Scand. J. Gastroenterol, 38, 1262 – 1267.